{"id":485581,"date":"2026-05-15T06:46:18","date_gmt":"2026-05-15T06:46:18","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/485581\/"},"modified":"2026-05-15T06:46:18","modified_gmt":"2026-05-15T06:46:18","slug":"eli-lilly-says-newly-approved-foundayo-lower-dose-zepbound-help-sustain-weight-loss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/485581\/","title":{"rendered":"Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss"},"content":{"rendered":"\n

Eli Lilly and Co. <\/strong>(NYSE:<\/a>LLY<\/a>) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss<\/a> after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound<\/a>.<\/p>\n

\u2022\u00a0Eli Lilly stock is showing upward bias. What should traders watch with LLY?<\/a><\/strong><\/p>\n

The company presented data from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies at the 33rd European Congress on Obesity. The findings were also published in The Lancet and Nature Medicine, respectively.<\/p>\n

SURMOUNT-MAINTAIN Meets Primary Goals<\/strong> <\/p>\n

In the SURMOUNT-MAINTAIN trial, both maintenance-dose Zepbound and a reduced 5 mg dose achieved the study’s primary and key secondary endpoints.<\/p>\n

The study evaluated whether continuing Zepbound after 60 weeks of initial treatment was superior to placebo in maintaining body weight reduction through week 112.<\/p>\n

Patients who remained on the maximum tolerated dose preserved all previously achieved weight loss. Those switched to the 5 mg dose maintained most of their reduction, regaining an average of 5.6 kilograms.<\/p>\n

Read Also: Roche, Eli Lilly Alzheimer’s Blood Test Cleared In Europe For Earlier Detection<\/a> <\/strong><\/p>\n

Foundayo Also Shows Positive Results<\/strong> <\/p>\n

The ATTAIN-MAINTAIN study found that patients switching to Foundayo also maintained most of their prior weight reduction after reaching a weight plateau in earlier SURMOUNT-5 treatment.<\/p>\n

By week 52, patients transitioning from Novo Nordisk A\/S<\/strong>\u2018 (NYSE:<\/a>NVO<\/a>) Wegovy maximum tolerated doses to Foundayo regained an average of 0.9 kilograms, while those switching from Zepbound maximum tolerated doses regained around 5 kilograms.<\/p>\n

Zepbound and Mounjaro Revenue Continues To Grow<\/strong> <\/p>\n

Mounjaro’s revenue increased 125% to $8.7 billion. U.S. revenue was $4.2 billion, an increase of 59%, reflecting strong demand, partially offset by lower realized prices<\/a>.<\/p>\n

U.S. Zepbound revenue increased 79% to $4.1 billion, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash pay prices.<\/p>\n

In April, Eli Lilly reported positive topline results<\/a> from its Phase 3 ACHIEVE-4 trial of its oral drug Foundayo (orforglipron) for weight loss.<\/p>\n

The study showed that orforglipron met the primary goal of cardiovascular safety compared with insulin glargine in adults with type 2 diabetes and obesity or overweight at elevated cardiovascular risk<\/a>.<\/p>\n

The study also indicated stronger reductions in blood sugar and body weight, positioning the therapy as a potential alternative to insulin-based treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were…\n","protected":false},"author":2,"featured_media":485582,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[212158,18,1465,212157,135,19,17,212155,462,212156,564],"class_list":["post-485581","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-attain-maintain","tag-eire","tag-eli-lilly","tag-foundayo","tag-health","tag-ie","tag-ireland","tag-maximum-tolerated-dose","tag-medication","tag-surmount-maintain","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116577251272077361","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/485581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=485581"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/485581\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/485582"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=485581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=485581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=485581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}